Financial Solutions Advisory Group Inc. Purchases New Stake in Novo Nordisk A/S $NVO

Financial Solutions Advisory Group Inc. acquired a new position in shares of Novo Nordisk A/S (NYSE:NVO) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 17,177 shares of the company’s stock, valued at approximately $631,000.

Other hedge funds have also recently bought and sold shares of the company. Godfrey Financial Associates Inc. bought a new stake in shares of Novo Nordisk A/S during the 4th quarter worth approximately $25,000. Scarborough Advisors LLC acquired a new position in Novo Nordisk A/S during the first quarter valued at approximately $26,000. WealthCollab LLC lifted its stake in Novo Nordisk A/S by 93.5% during the fourth quarter. WealthCollab LLC now owns 538 shares of the company’s stock worth $27,000 after purchasing an additional 260 shares during the last quarter. American National Bank & Trust acquired a new stake in shares of Novo Nordisk A/S in the 4th quarter valued at $28,000. Finally, Maseco LLP bought a new position in shares of Novo Nordisk A/S in the 4th quarter valued at $29,000. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Trading Down 8.5%

Shares of NVO stock opened at $47.20 on Friday. The stock has a market cap of $210.74 billion, a price-to-earnings ratio of 11.08, a PEG ratio of 4.30 and a beta of 0.77. The stock has a 50-day moving average of $46.92 and a 200-day moving average of $45.50. The company has a current ratio of 0.79, a quick ratio of 0.56 and a debt-to-equity ratio of 0.59. Novo Nordisk A/S has a 1-year low of $35.12 and a 1-year high of $64.16.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Tuesday, March 31st. The company reported $1.03 earnings per share for the quarter. The business had revenue of $10.85 billion during the quarter. Novo Nordisk A/S had a net margin of 37.23% and a return on equity of 63.31%. On average, equities research analysts forecast that Novo Nordisk A/S will post 3.38 earnings per share for the current year.

Key Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk’s existing obesity business remains a key support. The company recently received European approval for a once-daily Wegovy pill and partnered with Crux to expand access to Wegovy through U.S. employer health plans, potentially broadening distribution and affordability. Novo Nordisk Teams Up With Crux To Expand Wegovy Access
• Neutral Sentiment: Some investor commentary indicates that Novo Nordisk’s current revenue drivers, particularly its GLP-1 medicines, remain intact despite the pipeline setback. However, the failed trial increases reliance on those products for future growth. NVO Stock Slumps After Late-Stage Trial Fails Primary Goal
• Negative Sentiment: In the Phase 3 ZEUS trial, ziltivekimab failed to significantly reduce major adverse cardiovascular events versus placebo in patients with cardiovascular disease, chronic kidney disease and inflammation. The result eliminates or reduces the near-term commercial potential of a drug intended to expand Novo Nordisk’s cardiovascular portfolio. Novo Nordisk’s Inflammation Drug Fails to Reduce Cardiovascular Risk in Trial
• Negative Sentiment: The setback is weighing on investor confidence in Novo Nordisk’s pipeline and has pushed the stock lower as markets reassess future growth and valuation. Novo Nordisk Shares Dive After Heart Medicine Fails Trial
• Negative Sentiment: Erste Group Bank also trimmed its fiscal 2026 earnings estimate to $3.20 per share from $3.22, below the $3.39 consensus estimate, adding to the cautious outlook. Novo Nordisk Analyst Estimate Update

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on NVO shares. Zacks Research downgraded Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a research report on Monday, July 13th. Nordea Equity Research upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Friday, June 19th. Wall Street Zen downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Saturday, June 20th. Weiss Ratings reissued a “sell (d+)” rating on shares of Novo Nordisk A/S in a report on Monday, July 20th. Finally, Citigroup restated a “neutral” rating on shares of Novo Nordisk A/S in a research note on Monday, July 20th. Five equities research analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, Novo Nordisk A/S presently has an average rating of “Hold” and an average price target of $65.56.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.